Taiwan Advance Bio-Pharmaceutical (ROCO:4186) EBIT : NT$28.3 Mil (TTM As of Jun. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Taiwan Advance Bio-Pharmaceutical EBIT?

Taiwan Advance Bio-Pharmaceutical's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-0.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$28.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Taiwan Advance Bio-Pharmaceutical's annualized ROC % for the quarter that ended in Jun. 2024 was -0.35%. Taiwan Advance Bio-Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -0.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Taiwan Advance Bio-Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 1.78%.

Taiwan Advance Bio-Pharmaceutical EBIT Historical Data

The historical data trend for Taiwan Advance Bio-Pharmaceutical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Advance Bio-Pharmaceutical EBIT Chart

Taiwan Advance Bio-Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-163.07

-72.69

-107.01

9.82

-4.09

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															10.63	-0.81	-33.00	28.91	-0.63

Competitive Comparison of Taiwan Advance Bio-Pharmaceutical's EBIT

For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT falls into.

Taiwan Advance Bio-Pharmaceutical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$28.3 Mil.

Taiwan Advance Bio-Pharmaceutical (ROCO:4186) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Taiwan Advance Bio-Pharmaceutical's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-2.55 * ( 1 - 0% )	/	( (754.299	+	715.957)	/ 2 )
=	-2.55	/	735.128
=	-0.35 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	748.571	-	51.794	-	( 182.136	-	max(0, 316.821	-	259.299	+	182.136	))
=	754.299

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	699.318	-	25.8	-	( 138.508	-	max(0, 284.702	-	242.263	+	138.508	))
=	715.957

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Taiwan Advance Bio-Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.264	/	( ( (247.506 + max(-9.841, 0))	+	(241.381 + max(40.776, 0)) )	/	2 )
=	-1.264	/	( ( 247.506	+	282.157 )	/	2 )
=	-1.264	/	264.8315
=	-0.48 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(48.414	+	21.171	+	4.154)	-	(51.794	+	0	+	31.786)
=	-9.841

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(72.736	+	20.872	+	6.938)	-	(25.8	+	0	+	33.97)
=	40.776

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Taiwan Advance Bio-Pharmaceutical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	28.277	/	1592.434
	=	1.78 %

Taiwan Advance Bio-Pharmaceutical EBIT Related Terms

Thank you for viewing the detailed overview of Taiwan Advance Bio-Pharmaceutical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiwan Advance Bio-Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Advance Bio-Pharmaceutical Inc (ROCO:4186) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F., No.25, Ln. 169, Kangning Street, Xizhi Dist, New Taipei City, TWN, 22180

Website

http://www.abc-residue.com

Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's product includes Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.

Taiwan Advance Bio-Pharmaceutical Headlines

No Headlines